Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novozymes A/S raises FY 2014 financial guidance


Thursday, 24 Apr 2014 02:00am EDT 

Novozymes A/S:Says it has increased its full-year 2014 profit outlook.Says it expects FY 2014 sales growth in Danish crowns in a range of between 4 pct and 6 pct and FY 2014 organic sales growth in a range of between 6 pct and 9 pct.Sees FY 2014 EBIT growth of between 8 pct and 10 pct and FY 2014 EBIT margin of about 26 pct.Sees FY 2014 net profit growth of between 8 pct and 10 pct and FY 2014 free cash flow before acquisitions of between 3,300 mln Danish crowns and 3,400 mln Danish crowns.Says previously expected FY 2014 sales growth in Danish crowns of between 4 pct and 7 pct, FY 2014 organic sales growth of between 6 pct and 9 pct, FY 2014 EBIT growth of between 6 pct and 9 pct, FY 2014 EBIT margin of between 25 pct and 26 pct.Says previously expected FY 2014 net profit growth of between 6 pct and 9 pct, FY 2014 free cash flow before acquisitions of between 3,200 mln crowns and 3,300 mln crowns.